Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05822713
Other study ID # QLG2069-AMS-301
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date April 29, 2023
Est. completion date December 31, 2023

Study information

Verified date April 2023
Source Qilu Pharmaceutical (Hainan) Co., Ltd.
Contact yi feng
Phone 010-88325988
Email yifeng65@sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A comparison of the efficacy of Amisulpride and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 516
Est. completion date December 31, 2023
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: Inclusion Criteria: 1. Participant understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent. 2. Male or female patients = 18 years of age and =75 years of age. 3. 18<BMI=30kg/m^2,And weigh more than 45kg 4. Patients undergoing elective surgery(laparoscopic gynecological or abdominal surgery) under general anaesthesia requiring,and inhalation anesthesia is maintained for more than 1 hour, but patients who receive purely diagnostic surgery cannot be enrolled; 5. Patients with at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness Habitual non-smoking status Female sex Expected to receive opioid analgesia post-operatively 6. American Society of Anesthesiologists (ASA) risk score I-III - Exclusion Criteria: 1. Patients undergoing day case surgery 2. Patients undergoing intra-thoracic, transplant or central nervous system surgery or any surgery where post-operative emesis may pose a significant danger to the patient 3. Patients planned to receive only a local anaesthetic and/or regional neuraxial (intrathecal or epidural) block 4. Patients who are scheduled to be transferred to the ICU after surgery; 5. Patients who are expected to need a naso- or oral-gastric tube in situ after surgery is completed 6. Patients who have a documented, clinically significant cardiac arrhythmia or congenital long QT syndrome(Male= 450 ms female= 460ms). 7. Adequate hepatic and renal function, Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) = 2.5 x upper limit normal (ULN),Bilirubin = 1.5 x ULN,Creatinine = 1.5x ULN 8. Patients who have received Amisulpride active ingredient for any indication within the last 2 weeks 9. Patients who are allergic to Amisulpride active ingredient or any of the excipients of Amisulpride 10. Patients with a significant, ongoing history of vestibular disease or dizziness 11. Intestinal obstruction 12. Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma or breast cancer) or phaeochromocytoma. 13. Patients with pre-existing nausea or vomiting in the 24 hours before surgery 14. Patients treated with regular anti-emetic therapy including corticosteroids 15. Patients being treated with medications which could induce torsades de pointes, including Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and other medications such as bepridil, cisapride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin 16. Patients being treated with levodopa or other dopamine drugs 17. Patients who are pregnant or breast feeding. 18. Participant who has a history of drug or alcohol abuse within 6 months before randomization 19. Patients diagnosed with Parkinson's disease ,Patients with a history of epilepsy. 20. Patients who have received anti-cancer chemotherapy in the previous 4 weeks of surgery 21. Patients who have participated in other clinical research trials within 3 months before randomization 22. Participant who may increase study-related risks or interfere with the interpretation of study results in the opinion of the investigator, who are considered unsuitable for enrollment by the investigator and/or the sponsor.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Amisulpride
5mg/2ml
Amisulpride Placebo
2ml

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Qilu Pharmaceutical (Hainan) Co., Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint was the composite measure complete response defined as no episodes of emesis (vomiting or retching) and no use of rescue medication in the first 24h after wound closure 24 hours after the end of surgery
Secondary Incidence of no Nausea Count of patients experiencing an episode of no nausea scored < 1 of 0-10 verbal response scale during the 24 hours period after the completion of surgery 24 hours after end of surgery
Secondary Incidence of moderate and severe Nausea Count of participants with nausea score > 4 on 0-10 verbal response scale 24 hours after end of surgery
Secondary Incidence of Emesis (Vomiting/Retching) An assessment of a participant experiencing an episode of emesis (vomiting/ retching) during the 24hours after the completion of the surgery 24 hours after end of surgery
Secondary Use of Rescue Medication 24 hours after end of surgery
Secondary Time to First Violation of Criteria for PONV Criteria for PONV are any episode of emesis or use of rescue medication in the 24 hours after the end of surgery 24 hours after end of surgery
See also
  Status Clinical Trial Phase
Recruiting NCT01945502 - Nasopharyngeal Packing and Rhinologic Surgery. N/A
Completed NCT01840254 - Effect of Combination Dexmedetomidine Added to Fentanyl-based Intravenous Patient-controlled Analgesia on Nausea Vomiting in Highly Susceptible Patients Undergoing Lumbar Spinal Surgery: Prospective Double Blinded Randomized Controlled Trial N/A
Completed NCT00760253 - Compare the Side Effects and Difference Awake Level of Three TCI Propofol Formula in TVOR Patients N/A
Completed NCT00772226 - The Use of Music as Pain Therapy in Patients Undergoing Laparoscopic Cholecystectomy in a Day Care Unit Phase 3
Recruiting NCT03783182 - Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy Phase 4
Recruiting NCT03835234 - Incidence and Factors Associated With PONV in Regional Anaesthesia
Recruiting NCT04191694 - Chewing Gum to Prevent Nausea and Vomiting After Caesarean Section Under Spinal Anaesthesia N/A
Completed NCT02468323 - Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia Phase 4
Recruiting NCT05596695 - Minimisation of Blood Pressure Variability and Postoperative Nausea and Vomiting N/A
Recruiting NCT04570592 - Granisetron vs Granisetron and Dexamethasone on the Reduction of Postoperative Nausea and Vomiting Phase 2
Completed NCT02116257 - The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV N/A
Not yet recruiting NCT05396716 - Acupoint Stimulation Alleviates Postoperative Nausea and Vomiting N/A
Active, not recruiting NCT00892996 - Efficacy of Prevention for Postoperative Nausea and Vomiting After Intrathecal Morphine in Cesarean Section N/A
Recruiting NCT04866121 - Acupuncture for Prevention of Postoperative Nausea and Vomiting N/A
Completed NCT02809378 - The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of PONV Phase 4
Completed NCT05408676 - Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer Surgery N/A
Completed NCT01991821 - European Phase III Study of APD421 in PONV Phase 3
Completed NCT00952133 - Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV Phase 4
Completed NCT04054479 - Penehyclidine for PONV Prophylaxis After Strabismus Surgery Phase 4
Completed NCT05540236 - Effects of Auricular Acupressure on the Management of Postoperative Nausea and Vomiting After Gynecological Laparoscopic Surgeries N/A